Literature DB >> 33450086

Evaluation of intravenous to oral antimicrobial switch at a hospital with a tightly regulated antimicrobial stewardship program.

Sharmila Khumra1,2,3, Andrew A Mahony2,4, Phillip J Bergen3,5, Rohan A Elliott1,3.   

Abstract

Timely intravenous (IV) to oral antimicrobial switch (IV-oral-switch) is a key antimicrobial stewardship (AMS) strategy. We aimed to explore concordance with IV-oral-switch guidelines in the context of a long-standing, tightly regulated AMS program. Data was retrospectively collected for 107 adult general medical and surgical patients in an Australian hospital. Median duration of IV antimicrobial courses before switching to oral therapy was 3 days (interquartile range [IQR] 2.25-5.00). Timely IV-oral-switch occurred in 57% (n = 61) of patients. The median delay to switching was 0 days (IQR 0 to 1.25). In most courses (92/106, 86.8%), the choice of oral alternative after switching was appropriate. In 45% (47/105) of courses, total duration of therapy (IV plus oral) exceeded the recommended duration by >1.0 day. Excessive IV antimicrobial duration was uncommon at a hospital with a tightly regulated AMS program. Total duration of therapy was identified as an AMS target for improvement.
© 2021 British Pharmacological Society.

Entities:  

Keywords:  antimicrobial stewardship; antimicrobials; guidelines; hospital; preauthoriziation; switch therapy

Year:  2021        PMID: 33450086     DOI: 10.1111/bcp.14734

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  2 in total

Review 1.  From basic to advanced computerised intravenous to oral switch for paracetamol and antibiotics: an interrupted time series analysis.

Authors:  Charlotte Quintens; Marie Coenen; Peter Declercq; Minne Casteels; Willy E Peetermans; Isabel Spriet
Journal:  BMJ Open       Date:  2022-04-08       Impact factor: 2.692

2.  Coaching ward pharmacists in antimicrobial stewardship: A pilot study.

Authors:  Sharmila Khumra; Andrew A Mahony; Kay Stewart; Phillip J Bergen; Rohan A Elliott
Journal:  Explor Res Clin Soc Pharm       Date:  2022-03-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.